Journal
TRANSPLANT INFECTIOUS DISEASE
Volume 17, Issue 1, Pages 147-153Publisher
WILEY-BLACKWELL
DOI: 10.1111/tid.12339
Keywords
HIV; HCV coinfection; liver transplant; c-ART; cirrhosis; antiretrovirals; therapaeutic drug monitoring
Categories
Ask authors/readers for more resources
Since the introduction of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection is no longer a contraindication for solid organ transplantation. In HIV/hepatitis C virus (HCV)-coinfected patients undergoing liver transplantation, HCV-related cirrhosis, drug-drug interactions, and calcineurin inhibitors-related toxicity affect clinical outcomes. Therapeutic drug monitoring can be useful to assess antiretroviral over- or underexposure in this cohort. We report the clinical characteristics along with antiretroviral trough levels of maraviroc, darunavir, and etravirine in 3 HIV/HCV-coinfected liver transplant recipients who developed post-transplant liver cirrhosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available